Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED manages 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 pending office actions are split between 2 distinct examiners. The workload is also divided across 2 distinct art units, indicating no concentration in a single department. PRAGANI, RAJAN is the busiest examiner, holding 1 busiest examiner pending office action. This represents part of the 2 pending office actions for the company. The other action is handled by the second of the 2 distinct examiners.
With 2 pending office actions in 2 distinct art units, the company must navigate two different technical environments. The involvement of 2 distinct examiners means BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED must address two separate sets of examiner expectations within the biotechnology field. This distribution across 2 distinct examiners and 2 distinct art units requires a versatile approach to prosecution. Practitioners should be mindful that each of the 2 pending office actions is being evaluated in a unique environment. By addressing the specific concerns of both PRAGANI, RAJAN and the other examiner, the company can navigate the 2 distinct art units effectively. The lack of overlap between the 2 pending office actions ensures that each case is treated as a distinct technical challenge.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PRAGANI, RAJAN | 1 | 52.4% | +71.4% |
| ZINGARELLI, SANDRA | 1 | 6.7% | +46.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18283926 | LACTOBACILLUS RHAMNOSUS, FERMENT LYSATE FOR REGULATING SKIN MICROECOLOGY, PREPARATION METHOD, AND APPLICATION | ZINGARELLI, SANDRA | 28d |
| 18993723 | MOISTURE-LOCKING AND REPAIRING COMPOSITION FOR HAIR AND USE THEREOF | PRAGANI, RAJAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18283926 | LACTOBACILLUS RHAMNOSUS, FERMENT LYSATE FOR REGULATING SKIN MICROECOLOGY, PREPARATION METHOD, AND APPLICATION | ZINGARELLI, SANDRA | 28d |
| 18993723 | MOISTURE-LOCKING AND REPAIRING COMPOSITION FOR HAIR AND USE THEREOF | PRAGANI, RAJAN | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18993723 | MOISTURE-LOCKING AND REPAIRING COMPOSITION FOR HAIR AND USE THEREOF | PRAGANI, RAJAN | 1614 | §101§103§112 | Non-Final OA | — | Pending | Jan 13, 2025 |
| 18283926 | LACTOBACILLUS RHAMNOSUS, FERMENT LYSATE FOR REGULATING SKIN MICROECOLOGY, PREPARATION METHOD, AND APPLICATION | ZINGARELLI, SANDRA | 1653 | §101§102§103§112 | Non-Final OA | 28d | Pending | Sep 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Rajan Pragani has the most, with 1 of BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
